Furazolidone Manufacturing Plant Project Report 2025: Market by Region, Market by Application, Key Players, Pre-feasibility, Capital Investment Costs, Production Cost Analysis, Expenditure Projections, Return on Investment (ROI), Economic Feasibility, CAPEX, OPEX, Plant Machinery Cost

Furazolidone Manufacturing Plant Project Report 2025: Cost Analysis & ROI

Furazolidone Manufacturing Plant Project Report by Procurement Resource thoroughly focuses on every detail that encompasses the cost of manufacturing. Our extensive cost model meticulously covers breaking down Furazolidone plant capital cost around raw materials, labour, technology, and manufacturing expenses. This enables precise cost structure optimization and helps in identifying effective strategies to reduce the overall Furazolidone manufacturing plant cost and the cash cost of manufacturing.

Planning to Set Up a Furazolidone Plant? Request a Free Sample Project Report Now!
 

Furazolidone is a synthetic antimicrobial agent belonging to the nitrofuran class of antibiotics. It has a broad spectrum of activity against various bacterial and protozoan infections. It works by inhibiting bacterial enzyme systems. Historically, it was used in both human and veterinary medicine. However, its use in food-producing animals has been banned in many major regions, including the United States, the European Union, and Australia. It is banned in these regions due to significant concerns regarding its potential carcinogenic (cancer-causing) properties. Its current production is limited and primarily serves specific, limited markets where its use is still permitted.
 

Applications of Furazolidone

The current industrial applications for furazolidone are highly restricted and focused almost exclusively on veterinary medicine in specific countries.

• Veterinary Medicine: Furazolidone is widely used as a feed or water additive for the treatment and prevention of enteric (gut) infections in livestock. It is effective against:
  • Bacterial enteritis in swine (pigs) caused by E. coli or Salmonella.
  • Fowl typhoid and pullorum disease in poultry.
• Aquaculture: It is also used in some countries to control bacterial and protozoan infections in fish and shrimp farming.
• Research Chemical: It is often sold as a reference standard and laboratory chemical for research purposes.
• Human Medicine (Obsolete/Rare): Its use in humans for treating bacterial or protozoal diarrhoea is now outdated in most of the world due to safety concerns, although it may still be available in a few countries.
   

Top 3 Global Manufacturers of Furazolidone

Major multinational pharmaceutical companies have ceased Furazolidone production, due to the widespread regulatory bans. The global supply is now dominated by a few specialised chemical and veterinary API manufacturers, primarily based in Asia. Leading global manufacturers include:

• Hebei Veyong Animal Pharmaceutical Co., Ltd.
• Hubei Kexing Medical & Chemical Co., Ltd.
• Shandong Jincheng Pharmaceutical Group Co., Ltd.
   

Feedstock and Raw Material Dynamics for Furazolidone Manufacturing

The production cost analysis for furazolidone is based on a multi-step chemical synthesis that assembles the molecule from several key intermediates.

• 2-Hydrazinoethanol: It is a key starting material that is used to build the central oxazolidinone ring of the molecule.
• Diethyloxalate: A common commodity chemical reagent used in the initial condensation step with 2-hydrazinoethanol.
• Benzaldehyde: An aromatic aldehyde used as a protecting group for the hydrazine intermediate.
• 5-Nitrofurfurol: It is the most crucial and complex precursor. It is a derivative of furan (which is often derived from agricultural byproducts) that has been nitrated. This component provides the nitrofuran moiety that is essential for the drug's antimicrobial activity.
• Solvents and Reagents: The synthesis also requires various other industrial chemicals for the different reaction, extraction, and purification steps.
   

Market Drivers and Major Restraints for Furazolidone

The market for furazolidone is a limited market which is entirely defined by its regulatory restraints.

• Low Cost (Driver in Limited Markets): In countries where it is still permitted, furazolidone is a very low-cost, broad-spectrum antimicrobial. This cost-effectiveness is its only significant market driver, particularly in price-sensitive agricultural sectors.
• Global Regulatory Bans (Primary Market Restraint): The single most significant factor impacting the market is the widespread prohibition of furazolidone in food-producing animals in most major developed nations (including the US, EU, Canada, and Australia). These bans are due to the finding that it is a carcinogen, with residues posing a risk to human consumers.
• Consumer Demand for Antibiotic-Free Meat: A powerful global trend in consumer behaviour is the demand for meat and poultry raised without the use of any antibiotics. This is forcing livestock producers to seek alternatives to all antimicrobial feed additives, further reducing the market for furazolidone.
• Availability of Safer Alternatives: The development of newer, safer, and more effective veterinary antibiotics and feed additives has provided many superior alternatives, making furazolidone largely obsolete from a clinical and safety standpoint.
   

CAPEX and OPEX in Furazolidone Manufacturing

The Furazolidone manufacturing plant cost covers the investment required for a speciality chemical facility capable of performing multi-step organic synthesis, including the handling of hazardous nitro-aromatic compounds.
 

CAPEX (Capital Expenditure)

The initial investment cost for a furazolidone API plant is moderate. The Furazolidone plant capital cost includes:

• Land and Site Preparation: A suitable industrial site zoned for chemical production.
• Building and Infrastructure: cGMP-compliant (for pharmaceutical-grade) or industrial-grade production buildings with dedicated suites for the various synthesis steps.
• Chemical Reactors: A series of versatile, jacketed, and agitated glass-lined or stainless-steel reactors to accommodate the multi-step synthesis.
• Purification and Isolation Equipment: Industrial crystalliser vessels, centrifuges or filter presses, and vacuum dryers for the purification and isolation of the final product.
• Utilities and Support Systems: Standard utilities including a steam boiler for heating, a cooling tower or chiller system, a purified water plant, and solvent recovery units.
• Pollution Control Equipment: A robust Effluent Treatment Plant (ETP) is required to handle and treat the chemical wastewater, particularly the nitro-compounds.
   

OPEX (Operating Expenses)

Manufacturing or operating expenses for furazolidone are primarily driven by the cost of its chemical raw materials.

• Raw Material Costs: The largest component of OPEX, comprised of the costs for the key intermediates, 2-hydroazinoethanol and 5-nitrofurfurol, as well as other reagents like diethyloxalate.
• Energy Costs: Standard energy consumption for heating and cooling the reactors, as well as for running the purification and drying equipment. This is a key factor in the cash cost of production.
• Labour Costs: A skilled workforce of chemical plant operators, engineers, and quality control chemists is required.
• Waste Treatment Costs: The operational cost of the ETP to treat and dispose of the chemical and solvent waste from the process.
• Fixed Costs: It includes the depreciation and amortisation of the chemical plant and equipment, property taxes, and insurance.
   

Manufacturing Process

This report comprises a thorough value chain evaluation for Furazolidone manufacturing and consists of an in-depth production cost analysis revolving around the industrial manufacturing process.

• Production from 2-Hydroazinoethanol: The manufacturing process of furazolidone begins with 2-hydroazinoethanol as the starting material. The process starts with the chemical reaction of 2-hydroazinoethanol with diethyloxalate to form 3-amino-2-oxazolidone. Then, the obtained compound, 3-amino-2-oxazolidone, is reacted with benzaldehyde to form the corresponding hydrazone (a protected intermediate). Further, the obtained intermediate compound undergoes purification, followed by reaction with 5-nitrofurfurol, which results in the formation of furazolidone as the final product.
   

Properties of Furazolidone

Furazolidone is a synthetic nitrofuran derivative. It is a stable, yellow crystalline solid, which is insoluble in water.
 

Physical Properties

• Appearance: A yellow, odourless, crystalline powder.
• Odour: Odourless.
• Molecular Formula: C8H7N3O5
• Molar Mass: 225.16 g/mol
• Melting Point: Its melting point is 275 degree Celsius, with decomposition.
• Boiling Point: Not applicable, as it decomposes at its melting point.
• Density: Its density is approximately 1.70 g/cm³
• Flash Point: Not applicable, as it is a non-flammable solid.
   

Chemical Properties

• Solubility: It is practically insoluble in water and most organic solvents. It is slightly soluble in dimethylformamide.
• Structure: The molecule's key chemical features are a nitrofuran ring (the furan ring with a nitro group) connected via an azomethine linkage (-C=N-) to an oxazolidinone ring.
• Stability: The solid is stable under normal ambient storage conditions but is sensitive to light and should be stored in light-resistant containers. It is also degraded by alkaline solutions.
• Mechanism of Action: As a nitrofuran, its chemical structure is reduced by bacterial enzymes (nitroreductases) inside the bacterial cell. This reduction creates highly reactive, short-lived toxic intermediates. These intermediates then attack and damage multiple cellular components, including bacterial DNA, ribosomes, and other macromolecules. This multi-target mechanism is responsible for its broad-spectrum antimicrobial activity.
• Toxicity: Its breakdown products are believed to be responsible for its carcinogenicity, which is the primary reason for its ban in food-producing animals.
   

Furazolidone Manufacturing Plant Report provides you with a detailed assessment of capital investment costs (CAPEX) and operational expenses (OPEX), generally measured as cost per metric ton (USD/MT). This approach ensures that your investment decisions are aligned with the latest industry standards and economic feasibility metrics, enhancing your manufacturing efficiency and financial planning. 

Apart from that, this Furazolidone manufacturing plant report also covers the leading technology providers that help you plan a robust plan of action related to Furazolidone manufacturing plant and its production process(es), and also by helping you with an in-depth supplier database. This report provides exclusive insights into the best manufacturing practices for Furazolidone and technology implementation costs. This report also covers operational cash flow, fixed and variable costs, and detailed break-even point analysis, ensuring that your manufacturing process is not only efficient but also economically viable in the competitive market landscape.

In addition to operational insights, the Furazolidone manufacturing plant report also comprehensively focuses on lifecycle cost analysis, maintenance costs, and energy consumption costs, which are critical for maintaining long-term sustainability and profitability. Our manufacturing cost analysis extends to include regulatory compliance costs, inventory holding costs, and logistics and distribution costs, providing a holistic view of the potential expenses and savings.

We at Procurement Resource ensure that this report is not only cost-efficient, environmentally sustainable, and aligned with the latest technological advancements but also that you are equipped with all necessary tools to optimize supply chain operations, manage risks effectively, and achieve superior market positioning for Furazolidone.
 

Key Insights and Report Highlights

Key Questions Covered in our Furazolidone Manufacturing Plant Report

• How can the cost of producing Furazolidone be minimized, cash costs reduced, and manufacturing expenses managed efficiently to maximize overall efficiency?
• What is the estimated Furazolidone manufacturing plant cost?
• What are the initial investment and capital expenditure requirements for setting up a Furazolidone manufacturing plant, and how do these investments affect economic feasibility and ROI?
• How do we select and integrate technology providers to optimize the production process of Furazolidone, and what are the associated implementation costs?
• How can operational cash flow be managed, and what strategies are recommended to balance fixed and variable costs during the operational phase of Furazolidone manufacturing?
• How do market price fluctuations impact the profitability and cost per metric ton (USD/MT) for Furazolidone, and what pricing strategy adjustments are necessary?
• What are the lifecycle costs and break-even points for Furazolidone manufacturing, and which production efficiency metrics are critical for success?
• What strategies are in place to optimize the supply chain and manage inventory, ensuring regulatory compliance and minimizing energy consumption costs?
• How can labor efficiency be optimized, and what measures are in place to enhance quality control and minimize material waste?
• What are the logistics and distribution costs, what financial and environmental risks are associated with entering new markets, and how can these be mitigated?
• What are the costs and benefits associated with technology upgrades, modernization, and protecting intellectual property in Furazolidone manufacturing?
• What types of insurance are required, and what are the comprehensive risk mitigation costs for Furazolidone manufacturing?